OUR PEOPLE
Emily Mrig, PhD
Assistant Professor
School of Pharmacy
490 Illinois Street, #32N
San Francisco, CA 94158
Image
Education and Training
Yale University,New Haven, CT, Post-Doctoral Fellowship - Health Policy & Management
University of Colorado,Denver, CO, MA - Medical Anthropology
University of Colorado,Denver, CO, PhD - Health & Behavioral Sciences
Scripps College,Claremont, CA, BA - History/ Hispanic Studies
Awards and Honors
Fredrick Hard Outstanding Thesis Award, Scripps College, 2004
American Dissertation Fellowship Prize, American Association of University Women (AAUW), 2018-2019
Outstanding Doctoral Student Award, Health & Behavioral Sciences Department, University of Colorado, Denver, 2019
Outstanding Doctoral Student Award, College of Liberal Arts & Sciences, University of Colorado, Denver, 2019
Health Disparities Research Institute Scholar, NIH- National Institute on Minority Health and Health Disparities, 2021
Population Health & Health Equity Scholars Award, University of California, San Francisco, 2023-2024
Overview
Dr. Emily Hammad Mrig is an Assistant Professor at the University of California San Francisco Department of Clinical Pharmacy and at the Center for Translational and Policy Research on Precision Medicine (TRANSPERS); she is also an associate faculty member at the UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) and the Institute for Health Policy Studies (IHPS). Before joining the UCSF faculty, Emily completed a postdoctoral fellowship in the Department of Health Policy and Management at the Yale University School of Public Health. Emily is an interdisciplinary scholar with diverse training and experience in public health, health policy, and social science that she applies to investigate inequities in healthcare access, especially in precision medicine, cancer, and end-of-life care. She focuses on the broader institutional, community, and policy factors shaping health disparities and the possibility of health policy interventions to produce effective change.
Emily’s research engages qualitative and quantitative approaches, integrating multilevel perspectives on key health policy and insurance coverage issues to understand disparities and promote equitable access to health and healthcare. Current projects include an examination of patient-facing cost barriers to timely access to molecular diagnostics, including circulating tumor DNA (ctDNA) and targeted therapy, by integrating electronic health records (EHR) and geospatial data belonging to non-small cell lung cancer (NSCLC) patients. Emily is also leading a study on access to exome and whole-genome sequencing for patients with undiagnosed and rare genetic diseases. These studies provide a knowledge base for addressing disparities in access to precision medicine and generating timely evidence to guide equitable implementation of novel precision medicine technologies.
Emily’s research engages qualitative and quantitative approaches, integrating multilevel perspectives on key health policy and insurance coverage issues to understand disparities and promote equitable access to health and healthcare. Current projects include an examination of patient-facing cost barriers to timely access to molecular diagnostics, including circulating tumor DNA (ctDNA) and targeted therapy, by integrating electronic health records (EHR) and geospatial data belonging to non-small cell lung cancer (NSCLC) patients. Emily is also leading a study on access to exome and whole-genome sequencing for patients with undiagnosed and rare genetic diseases. These studies provide a knowledge base for addressing disparities in access to precision medicine and generating timely evidence to guide equitable implementation of novel precision medicine technologies.